CR20230183A - Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos - Google Patents

Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos

Info

Publication number
CR20230183A
CR20230183A CR20230183A CR20230183A CR20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A CR 20230183 A CR20230183 A CR 20230183A
Authority
CR
Costa Rica
Prior art keywords
certain
steps
biheteroaryl
elimination
need
Prior art date
Application number
CR20230183A
Other languages
English (en)
Inventor
Manuel Konrath
Christian Lautz
Diane Elizabeth Carrera
Ugo Jonathan Orcel
Katrin Monika Niedermann
Fabienne Hoffmann-Emery
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of CR20230183A publication Critical patent/CR20230183A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Catalysts (AREA)

Abstract

Se proporcionan procesos para preparar compuestos de biheteroarilo, incluso el compuesto de biheteroarilo 3-(difluorometoxi)-5-[2-(3,3-difluoropirrolidin-1-il)-6-[(1S,4S)-2-oxa-5-azabiciclo[2.2.1]heptan-5-il]pirimidin-4-il]piridin-2-amina. Entre otras ventajas, los procesos proporcionan: el uso de solventes que son relativamente no tóxicos y asequibles; el uso reducido de catalizadores de metales preciosos costosos; la reducción de la temperatura de reacción en ciertas etapas; el uso de agentes de oxidación relativamente no tóxicos; el uso de catalizadores de metales de transición asequibles; una reducción de las relaciones molares de ciertos reactivos, lo cual mejora la eficiencia del proceso y reduce los costos y desechos; concentraciones de reactivos significativamente más altas en ciertas etapas; eliminación de la necesidad de múltiples etapas de purificación cromatográfica; eliminación de la necesidad de ciertas etapas de extracción mediante el uso de solvente orgánico; y proporcionan un mayor rendimiento y una pureza mejorada.
CR20230183A 2020-10-02 2021-09-30 Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos CR20230183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087109P 2020-10-02 2020-10-02
PCT/US2021/053005 WO2022072721A1 (en) 2020-10-02 2021-09-30 Process for the preparation of biheteroaryl compounds and crystal forms thereof

Publications (1)

Publication Number Publication Date
CR20230183A true CR20230183A (es) 2023-06-14

Family

ID=78599176

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230183A CR20230183A (es) 2020-10-02 2021-09-30 Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos

Country Status (15)

Country Link
US (1) US20230312473A1 (es)
EP (1) EP4222154A1 (es)
JP (1) JP2023544037A (es)
KR (1) KR20230079123A (es)
CN (1) CN116744933A (es)
AU (1) AU2021353532A1 (es)
BR (1) BR112023005853A2 (es)
CA (1) CA3200566A1 (es)
CL (1) CL2023000945A1 (es)
CR (1) CR20230183A (es)
IL (1) IL301266A (es)
MX (1) MX2023003759A (es)
PE (1) PE20230781A1 (es)
SA (1) SA523440027B1 (es)
WO (1) WO2022072721A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
JPH07509250A (ja) 1992-07-27 1995-10-12 アメリカ合衆国 血液脳バリヤーへのリポソームの標的化
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004050062A2 (en) 2002-12-03 2004-06-17 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
TW201800403A (zh) 2013-05-01 2018-01-01 赫孚孟拉羅股份公司 二雜芳基化合物及其用途

Also Published As

Publication number Publication date
WO2022072721A1 (en) 2022-04-07
US20230312473A1 (en) 2023-10-05
MX2023003759A (es) 2023-04-24
CN116744933A (zh) 2023-09-12
CA3200566A1 (en) 2022-04-07
KR20230079123A (ko) 2023-06-05
PE20230781A1 (es) 2023-05-09
CL2023000945A1 (es) 2023-09-29
EP4222154A1 (en) 2023-08-09
BR112023005853A2 (pt) 2023-05-02
AU2021353532A8 (en) 2023-05-04
SA523440027B1 (ar) 2024-07-31
IL301266A (en) 2023-05-01
JP2023544037A (ja) 2023-10-19
AU2021353532A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
Sugimura et al. Diastereo-differentiating simmons-smith reaction using 2, 4-pentanediol as a chiral auxiliary
Yorimitsu et al. Radical reaction by a combination of phosphinic acid and a base in aqueous media
WO2006052688A3 (en) Catalyst and process for the metathesis of ethylene and butene to produce propylene
PL2125821T3 (pl) Sposób wytwarzania sildenafilu
Korwar et al. Chelation-directed C–H activation/C–C bond forming reactions catalyzed by Pd (ii) nanoparticles supported on multiwalled carbon nanotubes
SA523440027B1 (ar) عملية لتحضير مركبات أريل غير متجانس ثنائي وأشكال بلورية منها
RU2689126C2 (ru) Способ получения 3-метил-2-нитробензойной кислоты посредством окисления воздухом
CN101100450A (zh) 乙磺酰基乙腈的制备方法
MX2024008276A (es) Metodos para sintetizar compuestos de 1h-furo[3,2-b]imidazo[4,5-d] piridina.
Hashimoto et al. Catalytic process for efficient enantiodivergence of meso-N, N′-diacetyl-2-imidazolidinones and D LN-acetyl-2-oxazolidinones
Matsuo et al. Silica-catalyzed carboxylative cyclization of propargylic amines with CO2
Chen et al. Synthetic Studies on d-Biotin, Part 9. An Improved Asymmetric Synthetic Route to d-Biotin via Hoffmann–Roche Lactone–Thiolactone Approach
EP1595862A4 (en) PROCESS FOR PRODUCING IODIC COMPOUNDS AND PROCESS FOR PRODUCING HIGH-PURITY 5-IODO-2-METHILBENZOIC ACID
CN102391175A (zh) 2,2'-联吡啶-4,4'-二甲醛的绿色合成方法
CN111978245A (zh) 一种3-氟-2-异丁基吡啶的制备方法
CN110804012A (zh) 一种还原缩硫醛或缩硫酮脱硫的方法
CN113999239B (zh) 一种二氮杂桥化合物的合成方法
CN102718694A (zh) 3-氰基取代吲哚化合物及其合成方法
CN118852231A (zh) 一种非均相钯催化的C(sp2)-H键硅基化反应
Zhu et al. N-Bromoacetamide-mediated domino cyclization and elimination of homoallylic trichloroacetimidates: a novel approach toward the synthesis of 1-bromo-2-amino-3-butene derivatives
CN113087669A (zh) 一种4-氰基-5-溴嘧啶的制备方法
IL158151A0 (en) Method for preparing 7-quinolinyl-3, 5-dihydroxyhept-6-enoate
CN106928124B (zh) 沙格列汀中间体的制备方法
CN115353497A (zh) 一种2-（2-苯并噻唑）取代乙醇醚类化合物的合成方法
CN104016913A (zh) 一种制备酰胺化合物的方法